Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-A18 pembrolizumab plus chemoradiotherapy in high-risk locally advanced cervical cancer
2019-003152-37Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing Pembrolizumab plus concurrent chemoradiotherapy with Placebo plus concurrent chemoradiotherapy (2 arms). Primary endpoint: Progression-Free Survival (PFS) per RECIST 1.1 as assessed by investigator. Started Feb 2020; status: active.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2019-003152-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003152-37.